FIELD: pharmacology.
SUBSTANCE: composition according to the invention comprises a therapeutically effective amount of an analogue of S. aureus leukocidin A polypeptide, and may further comprise a therapeutically effective amount of the S. aureus leukocidin B polypeptide.
EFFECT: invention allows to increase the efficacy of S aureus infection treatment by obtaining the disclosed vaccine composition.
8 cl, 11 dwg, 5 ex
Title | Year | Author | Number |
---|---|---|---|
STAPHYLOCOCCUS AUREUS LEUKOCIDINS, THERAPEUTIC COMPOSITIONS AND THEIR APPLICATION | 2011 |
|
RU2677140C1 |
STAPHYLOCOCCUS AUREUS LEUKOCIDINS, THERAPEUTIC COMPOSITIONS AND THEIR USE | 2018 |
|
RU2795545C2 |
METHODS OF TREATMENT AND PREVENTION OF STAFILOCOCCA INFECTIONS OF GOLDEN AND RELATED DISTURBANCES | 2012 |
|
RU2635462C2 |
METHOD OF INHIBITING LEUCOCIDIN ED TOXICITY OF STAPHYLOCOCCUS AUREUS IN INDIVIDUAL | 2012 |
|
RU2609650C2 |
COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF INFECTIONS CAUSED BY STAPHYLOCOCCUS AUREUS | 2015 |
|
RU2636780C1 |
ANTIBODIES AGAINST TEICHOIC ACID CONJUGATE AND THEIR CONJUGATES | 2014 |
|
RU2687044C2 |
ANTIBODIES AGAINST STAPHYLOCOCCUS AUREUS LEUKOTOXINS | 2019 |
|
RU2805969C2 |
ANTIBODIES FOR SPECIFIC BINDING OF STAPHYLOCOCCUS AUREUS ALPHA-TOXIN AND METHODS OF APPLICATION | 2012 |
|
RU2620065C2 |
COMPOSITIONS AND METHODS OF TREATING FUNGAL AND BACTERIAL PATHOGENS | 2014 |
|
RU2717306C2 |
IMMUNOGENIC COMPOSITIONS OF STAPHYLOCOCCUS AUREUS ANTIGENS | 2010 |
|
RU2536981C9 |
Authors
Dates
2018-02-08—Published
2011-05-05—Filed